Document is current
Any future updates will be listed below
-
Authors
Sun, Yi
Revach, Or-yam
Anderson, Seth https://orcid.org/0000-0003-2419-0585
Kessler, Emily A. https://orcid.org/0000-0002-2608-6020
Wolfe, Clara H.
Jenney, Anne
Mills, Caitlin E. https://orcid.org/0000-0002-2608-4084
Robitschek, Emily J.
Davis, Thomas G. R.
Kim, Sarah
Fu, Amina
Ma, Xiang
Gwee, Jia https://orcid.org/0000-0001-9877-4546
Tiwari, Payal
Du, Peter P.
Sindurakar, Princy
Tian, Jun
Mehta, Arnav
Schneider, Alexis M. https://orcid.org/0000-0002-2158-6915
Yizhak, Keren https://orcid.org/0000-0002-4454-796X
Sade-Feldman, Moshe https://orcid.org/0000-0002-0022-0287
LaSalle, Thomas
Sharova, Tatyana
Xie, Hongyan
Liu, Shuming https://orcid.org/0000-0002-8882-4818
Michaud, William A.
Saad-Beretta, Rodrigo
Yates, Kathleen B. https://orcid.org/0000-0002-7383-5573
Iracheta-Vellve, Arvin https://orcid.org/0000-0002-6635-3904
Spetz, Johan K. E. https://orcid.org/0000-0002-5216-9786
Qin, Xingping https://orcid.org/0000-0003-3263-0843
Sarosiek, Kristopher A. https://orcid.org/0000-0002-4618-5085
Zhang, Gao https://orcid.org/0000-0001-8617-8886
Kim, Jong Wook
Su, Mack Y.
Cicerchia, Angelina M.
Rasmussen, Martin Q.
Klempner, Samuel J. https://orcid.org/0000-0002-4062-0808
Juric, Dejan https://orcid.org/0000-0003-2983-7704
Pai, Sara I.
Miller, David M.
Giobbie-Hurder, Anita
Chen, Jonathan H.
Pelka, Karin
Frederick, Dennie T.
Stinson, Susanna
Ivanova, Elena
Aref, Amir R.
Paweletz, Cloud P. https://orcid.org/0000-0002-2287-5663
Barbie, David A.
Sen, Debattama R. https://orcid.org/0000-0002-0947-8284
Fisher, David E.
Corcoran, Ryan B. https://orcid.org/0000-0001-8173-5778
Hacohen, Nir https://orcid.org/0000-0002-2349-2656
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
Flaherty, Keith T. https://orcid.org/0000-0002-3402-0478
Boland, Genevieve M.
Manguso, Robert T. https://orcid.org/0000-0003-1336-413X
Jenkins, Russell W. https://orcid.org/0000-0001-6110-2148
- License Information
-
More Information
Article History
Received: 16 July 2021
Accepted: 4 January 2023
First Online: 12 January 2023
Competing interests
: R.W.J. is a member of the advisory board for and has a financial interest in Xsphera Biosciences, a company focused on using ex vivo profiling technology to deliver functional, precision immune-oncology solutions for patients, providers and drug development companies. A.M. is a consultant for Third Rock Ventures, Asher Biotherapeutics and Abata Therapeutics; and holds equity in Asher Biotherapeutics and Abata Therapeutics. S.I.P. has received consultancy payments from Abbvie, Astrazeneca/MedImmune, Cue Biopharma, Fusion Pharmaceuticals, MSD/Merck, Newlink Genetics, Oncolys Biopharma, Replimmune, Scopus Biopharma and Sensei Biopharma; she has received grants/research support from Abbvie, Astrazeneca/MedImmune, Cue Biopharma, Merck and Tesaro. S.J.K. has served a consultant/advisory role for Eli Lilly, Merck, BMS, Astellas, Daiichi-Sankyo, Pieris and Natera; and owns stock in Turning Point Therapeutics. D.J. received consulting fees from Novartis, Genentech, Syros, Eisai, Vibliome, Mapkure and Relay Therapeutics; conducted contracted research with Novartis, Genentech, Syros, Pfizer, Eisai, Takeda, Pfizer, Ribon Therapeutics, Infinity, InventisBio and Arvinas; and has ownership interest in Relay Therapeutics and PIC Therapeutics. D.M.M. has received honoraria for participating on advisory boards for Checkpoint Therapeutics, EMD Serono, Castle Biosciences, Pfizer, Merck, Regeneron and Sanofi Genzyme; and owns stock in Checkpoint Therapeutics. D.E.F. has a financial interest in Soltego, a company developing salt-inducible kinase inhibitors for topical skin-darkening treatments that might be used for a broad set of human applications. R.T.M. consults for Bristol Myers Squibb. M.S.-F. receives research funding from Bristol-Meyers Squib.
